Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence rate of aniridia
3.2.1.2 Increasing awareness for rare diseases
3.2.1.3 Growing R&D investment
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Medication
5.2.1 Type
5.2.1.1 Eye drop
5.2.1.2 Ointments
5.2.1.3 Other medication types
5.2.2 Distribution channel
5.2.2.1 Hospital pharmacies
5.2.2.2 Retail pharmacies
5.2.2.3 Online pharmacies
5.3 Surgery
5.3.1 Surgery type
5.3.1.1 Keratoplasty
5.3.1.2 Artificial iris implantation
5.3.1.3 Glaucoma drainage devices
5.3.1.4 Trabeculectomy
5.3.1.5 Goniotomy
5.3.1.6 Other surgery types
5.3.2 End-user
5.3.2.1 Hospitals
5.3.2.2 Specialty clinics
5.3.2.3 Ambulatory surgical centers
5.3.2.4 Other end-users
Chapter 6 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Congenital aniridia
6.2.1 Isolated aniridia
6.2.2 WAGR syndrome
6.2.3 Gillespie syndrome
6.3 Acquired aniridia
Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Pediatric
7.3 Adult
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AbbVie Inc.
9.2 Bausch & Lomb Incorporated
9.3 F. Hoffmann-La Roche Ltd
9.4 HumanOptics AG
9.5 Johnson & Johnson Vision
9.6 MORCHER GmbH
9.7 Novartis AG
9.8 Ophtec
9.9 Pfizer Inc.
9.10 REPER-NN LTD.
Aniridia Treatment Market Trends
Advances in genetic testing and molecular diagnostics enable healthcare providers to tailor treatment strategies to the specific genetic mutations underlying aniridia caused by a faulty gene (PAX6) in individual patients. This personalized approach enhances treatment efficacy and patient outcomes, driving demand for targeted therapies and contributing to the expansion of the aniridia treatment market.
Thus, growing constant support from government along with increasing awareness pertaining to rare disease especially in developed countries will spur the market growth.
Transitional Care Management Services Market
U.S. Post-acute Care Market
U.S. Ambulatory Surgical Centers Market
ASEAN Medical and Wellness Tourism Market